Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Feasibility × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 1542 Neoplasms 1040 Colorectal Neoplasms 880 Carcinoma, Non-Small-Cell Lung 850 Stomach Neoplasms 678 Carcinoma, Hepatocellular 669 Lung Neoplasms 626 Prostatic Neoplasms 579 Pancreatic Neoplasms 479 Rectal Neoplasms 363 Neoplasm Metastasis 348 Ovarian Neoplasms 341 Colonic Neoplasms 335 Uterine Cervical Neoplasms 327 Recurrence 325 Leukemia, Myeloid, Acute 320 Esophageal Neoplasms 290 Multiple Myeloma 284 Lymphoma 275 Head and Neck Neoplasms 275 Melanoma 265 Precursor Cell Lymphoblastic Leukemia-Lymphoma 227 Brain Neoplasms 227 Urinary Bladder Neoplasms 217 Nasopharyngeal Carcinoma 190 Lymphoma, Large B-Cell, Diffuse 190 Leukemia 189 Liver Neoplasms 179 Glioblastoma 169 Squamous Cell Carcinoma of Head and Neck 166

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡